Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer
A prospective, open, one-arm clinical study to evaluate the efficacy and safety of jinyouli in the first-line treatment of advanced pancreatic cancer with albumin paclitaxel combined with S-1.Chemotherapy regimen: (1) chemotherapy: albumin paclitaxel, 120mg / m2, intravenous infusion for 30 minutes, D1. S-1, taken orally after meal, D1 - 14. (2) patients who met the input / discharge criteria were given jinyouli injections 24 hours after the end of intravenous infusion of albumin paclitaxel during the treatment period.
Advanced Pancreatic Cancer
DRUG: PEG-rhG-CSF
Incidence of degree 3-4 neutropenia in each cycle of chemotherapy, Incidence of degree 3-4 neutropenia in each cycle of chemotherapy, It lasts 4 cycles(each cycle is 21 days)
The incidence of febrile neutropenia in each cycle of chemotherapy, Febrile neutropenia (FN) is defined as oral temperature \>38.3 ° C (underarm temperature \>38.1 ° C) or continuous measurement of oral temperature \>38 ° C (underarm temperature \>37.8 ° C) in 2 h, and ANC \<0.5×10\^9/L, or expected to be \<0.5×10\^9/L, It lasts 4 cycles(each cycle is 21 days)|Incidence of chemotherapy dose adjustment due to neutropenia in each cycle of chemotherapy, Incidence of chemotherapy dose adjustment due to neutropenia in each cycle of chemotherapy, It lasts 4 cycles(each cycle is 21 days)|The proportion of patients hospitalized due to neutropenia, The proportion of patients hospitalized due to neutropenia, It lasts 4 cycles(each cycle is 21 days)|The proportion of patients receiving antibiotics during the entire chemotherapy period., The proportion of patients receiving antibiotics during the entire chemotherapy period., It lasts 4 cycles(each cycle is 21 days)
A prospective, open, one-arm clinical study to evaluate the efficacy and safety of jinyouli in the first-line treatment of advanced pancreatic cancer with albumin paclitaxel combined with S-1.Chemotherapy regimen: (1) chemotherapy: albumin paclitaxel, 120mg / m2, intravenous infusion for 30 minutes, D1. S-1, taken orally after meal, D1 - 14. (2) patients who met the input / discharge criteria were given jinyouli injections 24 hours after the end of intravenous infusion of albumin paclitaxel during the treatment period.